CompletedInterventional · Not applicableNCT04146428 ↗Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial
CompletedInterventional · Phase 2NCT05067582 ↗A Randomized, Double-Blind, Chronic Dosing (12-weeks), Two-Period, Placebo-Controlled, Crossover, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Two Doses of L1-79 for the Treatment of the Core Deficits in Social-Communication Interaction in Adolescents and Young Adults With Autism Spectrum DisorderKaren TangPIInterventionDrug: L1-79DatesJan 2022 – Jun 2024SponsorYamo PharmaceuticalsAutism Spectrum DisorderAutism
CompletedInterventional · Phase 2NCT05081245 ↗A Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD).Karen TangPIInterventionDrug: ML-004 (IR)/(ER) tablet · Drug: ML-004 PlaceboDatesSep 2022 – Mar 2026SponsorMapLight Therapeutics, IncAutism Spectrum Disorder